What is BioVie?
BioVie Inc. (NASDAQ: BIVI) operates as a clinical-stage biopharmaceutical firm dedicated to the development of innovative therapies for neurodegenerative disorders and advanced liver disease. Headquartered in Carson City, Nevada, the company is primarily focused on its lead candidate, bezisterim, which targets the inhibition of tumor necrosis factor alpha (TNF-α) to mitigate neuroinflammation and insulin resistance. These biological pathways are critical drivers in the progression of Alzheimer's and Parkinson's diseases. Furthermore, the company is advancing BIV201, currently in phase 2 trials, which aims to treat ascites associated with chronic liver cirrhosis. BioVie's market position is defined by its specialized approach to modulating inflammatory responses, positioning it as a strategic entity within the broader pharmaceutical landscape.
How much funding has BioVie raised?
BioVie has raised a total of $47.4M across 3 funding rounds:
Stock Offering
$16M
Private Equity
$18.8M
Grant
$12.6M
Stock Issuance/Offering (2020): $16M, investors not publicly disclosed
Private Equity (2024): $18.8M, investors not publicly disclosed
Grant (2024): $12.6M supported by U.S. Department of Defense
Key Investors in BioVie
U.S. Department of Defense
The U.S. Department of Defense is a federal executive department responsible for coordinating national security and overseeing the development of advanced technologies and infrastructure to protect national interests.
Undisclosed Investor
An institutional participant providing private equity backing to support the company's clinical-stage drug development programs.
Undisclosed Investor
A strategic participant in the company's stock issuance and offering rounds, contributing to the firm's overall capital structure.
What's next for BioVie?
Looking ahead, BioVie is poised to utilize its recent capital injection to expedite the clinical evaluation of its lead assets. The strategic roadmap involves advancing bezisterim through critical trial phases, with a clear emphasis on demonstrating efficacy in reducing neuroinflammation. As the company transitions through these development stages, the focus will remain on achieving regulatory milestones that validate its therapeutic platform. Investors and stakeholders are closely monitoring the progress of BIV201, as successful phase 2 outcomes could significantly enhance the company's valuation and long-term growth prospects. The integration of federal support and private equity backing provides a robust foundation for BioVie to scale its operations and potentially bring transformative treatments to patients suffering from chronic and debilitating conditions.
See full BioVie company page
